drug
tarlatamab
Marketedupdated 6mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
all catalysts(2)
Trials studying tarlatamab
- phase1Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
- phase2Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
- phase2Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- phase2Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)
- phase2Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
- phase2Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
- phase2Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
- phase3A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
News(10)
- Amgen starts MariTide autoinjector study as pivotal readouts approachWith the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjecto…biospace · 12d ago
- Molecular Partners to lay off up to 44% of workforce in radiotherapy pivotMolecular Partners plans to lay off up to 44% of its staff as it focuses its declining cash reserves on a radiotherapeutic pipeline led by an early-phase small cell lung cancer drug candidate.fiercebiotech · 18d ago
- A possible treatment for brain-eating amoebas, found in the seaBrain-eating amoebas are hard to treat and nearly always fatal. But researchers have isolated a compound that could help stop the disease.stat · 20d ago
- ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ dataAt one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.biopharma_dive · 21d ago
- ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancerWhen used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintena…biospace · 21d ago
- STAT+: The ESMO presentation everyone’s been waiting forModerna and Merck's 'presidential' presentation, and other news from Day 2 of the European Society for Medical Oncology meeting in Madrid.stat · 23d ago
- #ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trialMADRID — Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi slashed the chances of dying by 58% versus Imfinzi alone in the first-line maintenance setting in certain small cell lung cancer patie…endpoints · 23d ago
- Roche taps Zymeworks in up to $813M deal for preclinical T cell engagerAnother day, another Roche deal. The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell engager (TCE) that could go head-to-head with…endpoints · 24d ago
- Roche pays Zymeworks $55M for trispecific challenger to Amgen’s ImdelltraRoche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the rate and depth of responses achieved by Amgen’s Imdelltra.fiercebiotech · 25d ago
- ESMO: Boehringer builds case for late-phase rival to Amgen’s ImdelltraBoehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra that entered phase 3 this year.fiercebiotech · 26d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that